T. Rowe Price Investment Management’s Xenon Pharmaceuticals XENE Stock Holding History

T. Rowe Price Investment Management’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$55.4M	Buy	951,955 +404,342	+74%	+$18.6M	0.04%	334
2025 Q4	$24.5M	Sell	547,613 -51,500	-9%	-$2.16M	0.02%	463
2025 Q3	$24.1M	Buy	599,113 +522,170	+679%	+$18.4M	0.01%	484
2025 Q2	$2.41M	Sell	76,943 -720,043	-90%	-$23.5M	﹤0.01%	597
2025 Q1	$26.7M	Sell	796,986 -640,845	-45%	-$24.3M	0.02%	482
2024 Q4	$56.4M	Sell	1,437,831 -65,977	-4%	-$2.73M	0.03%	391
2024 Q3	$59.2M	Buy	1,503,808 +63,905	+4%	+$2.58M	0.04%	377
2024 Q2	$56.1M	Buy	1,439,903 +13,564	+1%	+$542K	0.04%	373
2024 Q1	$61.4M	Buy	1,426,339 +535,190	+60%	+$24.6M	0.04%	360
2023 Q4	$41M	Buy	+891,149	New	+$31.5M	0.03%	410

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Investment Management's XENE Position: Q1 2026 in Review

T. Rowe Price Investment Management increased its Xenon Pharmaceuticals (XENE) stake by 74% in Q1 2026, buying an estimated $18.6M and bringing the position to 951,955 shares worth $55.4M. The position accounts for 0.04% of the portfolio, ranked #334.

T. Rowe Price Investment Management first reported a position in XENE in Q4 2023 and has held it in 10 quarters since. The position peaked at $61.4M in Q1 2024. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

T. Rowe Price Investment Management held 951,955 shares of Xenon Pharmaceuticals worth $55.4M as of Q1 2026.
T. Rowe Price Investment Management bought 404,342 Xenon Pharmaceuticals shares in Q1 2026, an estimated $18.6M.
Xenon Pharmaceuticals made up 0.04% of T. Rowe Price Investment Management's portfolio in Q1 2026, its #334 holding.
T. Rowe Price Investment Management first reported a position in Xenon Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
T. Rowe Price Investment Management's Xenon Pharmaceuticals position peaked at $61.4M in Q1 2024.
290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2026, filed 15 May 2026.